Fragility fractures caused by osteoporosis can have devastating consequences on patients and their families, causing pain and immobility, as well as potential complications like blood clots, infections, and even untimely death.
Antiresorptive therapies are used to increase bone strength in individuals with osteoporosis. They include several classes of agents: bisphosphonates, estrogens, selective estrogen receptor modulators (SERMs), and monoclonal antibodies, such as denosumab. Available in oral and injectable forms, these agents are proven to prevent fractures and treat osteoporosis.
After a detailed evaluation of each patient’s medical conditions, prior treatment history, contributing factors, personal preferences, benefits, and risks, our experts will help each patient choose the most appropriate treatment for them.